Takeda Pharmaceuticals
| 9:00AM 9/02/2010
Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.
| 9:00AM 7/13/2010
On Tuesday, the FDA will convene a panel of experts to discuss GlaxoSmithKline's type II diabetes drug Avandia. Once a blockbuster, sales of the drug have dropped by more than half since studies suggested it significantly increases risk for serious heart problems.